Clinical Edge Journal Scan

Childhood atopic dermatitis is associated with increased fatigue


 

Key clinical point: Fatigue is a common symptom in children with atopic dermatitis (AD), particularly those with moderate-to-severe AD, and thus should be considered in clinical practice and trials.

Major finding: Most children had no (38.6%) or mild (32.1%) parent-proxy fatigue, but 27.2% had moderate fatigue and 2.0% had severe fatigue. Higher proportions of children with moderate-to-severe parent-proxy Patient-Reported Outcome Measurement Information System Pediatric fatigue scores were those with moderate (25.7%/1.4%) and severe (39.3%/5.4%) AD vs mild AD (18.0%/0.0%), as determined by Investigator’s Global Assessment, especially those with 5-6 (44.4%/0.0%) or 7 (44.2%/5.2%) nights of sleep disturbance from eczema.

Study details: This cross-sectional observational study included 248 children aged 0-17 years with AD.

Disclosures: This study was funded by the US National Institute of Arthritis and Musculoskeletal and Skin Diseases. The authors declared no conflicts of interest.

Source: Rangel SM et al. Prevalence and associations of fatigue in childhood atopic dermatitis: A cross-sectional study. J Eur Acad Dermatol Venereol. 2022 (Dec 21). Doi: 10.1111/jdv.18819

Recommended Reading

Commentary: Evaluating Recent Drug Developments in Atopic Dermatitis, January 2023
MDedge Dermatology
AAD unveils updated guidelines for topical AD treatment in adults
MDedge Dermatology
AD outcomes improved with lebrikizumab and topical steroids
MDedge Dermatology
Age-related atopic dermatitis phenotypes evaluated in study
MDedge Dermatology
Lebrikizumab+topical corticosteroid shows promise in moderate-to-severe atopic dermatitis
MDedge Dermatology
Abrocitinib rapidly relieves itch in moderate-to-severe atopic dermatitis
MDedge Dermatology
Baricitinib offers a long-term treatment option for moderate-to-severe atopic dermatitis
MDedge Dermatology
Long-term integrated safety of baricitinib in moderate-to-severe atopic dermatitis
MDedge Dermatology
Upadacitinib is effective in treating difficult-to-treat moderate-to-severe atopic dermatitis
MDedge Dermatology
Prolonged dupilumab therapy is safe and effective in moderate-to-severe atopic dermatitis
MDedge Dermatology